|
WO2017069980A1
|
|
Aminoisoxazoline compounds as agonists of alpha7-nicotinic acetylcholine receptors
|
|
WO2017031325A1
|
|
Oxadiazine compounds and methods of use thereof
|
|
US2017044155A1
|
|
Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
|
|
CN107847494A
|
|
Amino benzisoxazole compounds as the nicotinic acetylcholine receptors alpha7s of α 7
|
|
WO2015138689A1
|
|
Fused morpholinopyrimidines and methods of use thereof
|
|
WO2015109109A1
|
|
Fused morpholinopyrimidines and methods of use thereof
|
|
WO2015066697A1
|
|
Fused morpholinopyrimidines and methods of use thereof
|
|
WO2015066696A1
|
|
Fused morphlinopyrimidines and methods of use thereof
|
|
WO2015066371A1
|
|
SPIRO-OXADIAZOLINE COMPOUNDS AS AGONISTS OF α-7-NICOTINIC ACETYLCHOLINE RECEPTORS
|
|
TW201512201A
|
|
Polymorphs and salts of a compound
|
|
MX2014013491A
|
|
Methods of maintaining, treating or improving cognitive function.
|
|
CN105748484A
|
|
Methods of targeted treatment of frontotemporal lobar degeneration
|
|
AU2011305568A1
|
|
Imidazotriazinone compounds
|
|
EP3020716A1
|
|
Phenoxymethyl heterocyclic compounds
|
|
EP2540297A1
|
|
Treatment of Cognitive Disorders with (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
|
|
CN102131801A
|
|
1, 2 disubstituted heterocyclic compounds
|
